Press release content from Business Wire. The AP news staff was not involved in its creation.
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2
January 25, 2021 GMT
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2 (Photo: AchilleS Vaccines)
KALKARA, Malta & SIENA, Italy (BUSINESS WIRE) Jan 25, 2021
Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits.